Contrast Enhanced Ultrasonography (CEUS) of Patients With Crohn's Disease
NCT ID: NCT01074580
Last Updated: 2016-01-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
20 participants
OBSERVATIONAL
2009-11-30
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Contrast-Enhanced Ultrasound in Human Crohn's Disease
NCT02061163
Ultrasound Evaluation of Crohn's Disease
NCT03235180
Ultrasound Stiffness Imaging in Crohn's Disease
NCT01666626
A Comparative Study of MRI, US and CE for Assessing Treatment Response in Known Crohn's Disease
NCT03435016
Usefulness of Contrast-enhanced Ultrasound (CEUS) in Crohn's Disease Pediatric Patients
NCT04660136
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Deterioration, Crohn's disease
Patients \> 18 years old with a deterioration of Crohn's disease defined by CDAI \>150 and requiring treatment with systemic steroids or TNF alfa inhibitors
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* CDAI\>150
* Treated with systemic steroids or TNF alfa inhibitors
* Lesion found on ultrasound
Exclusion Criteria
* Pregnancy
* Acute coronary disease
* Unstable coronary disease
* Previous allergic reaction to SonoVue or its components
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Bergen
OTHER
Abbott
INDUSTRY
Haukeland University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Trygve Hausken, PhD
Role: STUDY_DIRECTOR
Nastional Center of Gastroenterological Ultrasonography, Haukeland University Hospital, Bergen, Norway
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Medicine, Haukeland University Hospital
Bergen, Hordaland, Norway
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
22209
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.